FLJ10540 is associated with tumor progression in nasopharyngeal carcinomas and contributes to nasopharyngeal cell proliferation, and metastasis via osteopontin/CD44 pathway

Table 2 Comparisons of FLJ10540 and osteopontin expressions between the subgroups of various clincopathological parameters

	FLJ10540 expression		p- value^a	Osteopontin expression		p- value^a
	Low	High		Low	High
	(n=42)	(n=21)		(n=47)	(n=16)
Age (year),			0.582			0.212
< 50	17	7		20	4
≥ 50	25	14		27	12
Gender			0.838			1.000
Male	31	16		35	12
Female	11	5		12	4
Histology			0.856			0.816
WHO type II	25	12		28	9
WHO type III	17	9		19	7
Tumor size			<0.001			<0.001
T1-T2	40	4		40	0
T3-T4	2	17		3	16
Nodal stage			0.001			0.007
N0-N1	34	7		35	6
N2-N3	8	14		12	10
AJCC staging			<0.001			<0.001
I-II	32	0		32	0
III-IV	10	21		15	16

Abbreviations: NPC naso-pharyngeal carcinoma; WHO World Healthy Organization; AJCC American Joint Committee on Cancer.
^ap-value from Chi-square or Fisher exact test. Statistically significant (p < 0.05).

ISSN: 1479-5876